drugset

drugset / Trial / NCT07211776

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

NCT07211776 ↗

Phase 3 Recruiting 99 enrolled Zai Lab (Shanghai) Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)

Timeline

Start: 2025-12-05
Primary completion: 2027-03-14
Completion: 2028-01-29

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ZL-1109	Unknown	—	Subcutaneous

Indications